United States Copper Index Fund vs GeneDx Holdings Corp — how do they compare? United States Copper Index Fund trades at $38.57, while GeneDx Holdings Corp trades at $64.57 (market cap $1.85B). The key difference: United States Copper Index Fund is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| CPER | WGS | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Technology |
52-Week High | $40.60 | $167.51 |
52-Week Low | $27.21 | $34.51 |
Market Cap | — | $1.85B |
Enterprise Value | — | $1.85B |
Signals from Pluang's Aura AI — not financial advice
CPER, the United States Copper Index Fund, trades at $37.94, down 0.13% on the day, with a bullish technical signal driven by moving averages. Recent news highlights copper's strong performance tied to AI and electrification demand, with articles from 24/7 Wall Street and Reuters in July 2026 noting copper's 33% annual gain and structural demand drivers. Key support and resistance cluster around $38.
The outlook for CPER remains positive given copper's fundamental role in energy transition and AI infrastructure, though risks include potential global manufacturing weakness and substitution threats from aluminum. Investor sentiment is buoyant, but price sensitivity to macroeconomic trends warrants caution.
GeneDx Holdings (WGS) trades at $63.85, down 2.73% amid multiple securities class action lawsuits alleging misleading acquisition performance disclosures. The stock shows bearish technical signals with support at $60 and resistance at $65. Fundamentally, the company reported negative net income of -$21.02M for 2025 despite revenue growth to $427.54M, with profitability metrics deteriorating significantly in 2026 projections.
Despite 91% analyst buy ratings and a $75.40 consensus target, substantial legal risks and negative earnings momentum create significant headwinds. The stock faces near-term pressure from litigation while long-term viability depends on reversing negative margin trends and resolving acquisition-related impairment issues that triggered the 49% stock decline cited in lawsuits.
Trailing returns across standard periods
Latest headlines on both assets
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →